CytomX Therapeutics’ Post

CX-2051 has amazing potential to bring benefit to EpCAM+ solid tumor patients, notably in CRC where there is significant unmet need. The program is a shining example of how CytomX Therapeutics applies our masked PROBODY platform to ADCs to increase therapeutic index by minimizing on-target, off-tumor toxicity. Particularly beneficial when the target also has broad healthy tissue expression (like EpCAM).

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers. Discovery of the clinical stage MTA-cooperative PRMT5 inhibitor AMG 193, which preferentially binds PRMT5 in the presence of MTA and has potent biochemical and cellular activity in MTAP-deleted cells across multiple cancer lineages. AMG 193 is demonstrating promising clinical activity, including confirmed partial responses in patients with MTAP-deleted solid tumors from an ongoing phase 1/2 study. https://lnkd.in/g43zvaiU

In solid tumors, the dense extracellular matrix (ECM) composed of cancer-associated fibroblasts (CAFs) blocks drug penetration and reduces therapeutic efficacy. In view of this, the researchers designed a sequential therapeutic strategy to reshape the ECM through a CAF modifier (dasatinib, DAS) to promote the penetration of immunogenic cell death (ICD) inducers through apoptotic vesicles (Epirubicin (Epi)), thereby improving the therapeutic effect on breast cancer. https://lnkd.in/gMXfAryK

In view of the clinical problem of high recurrence and metastasis rate of triple-negative breast cancer, it is proposed to construct a nano-activator that can enhance microwave thermodynamic-chemotherapy to effectively kill the primary tumor and improve the immunosuppressive microenvironment at the same time. A MOF-based MPPT nanoactivator was constructed by encapsulating the chemotherapy drug Pyrotinib and the immunosuppressant PD-1/PD-L1 inhibitor 2 into MnCa-metal organic framework (MOF), and further coupling the targeting molecule triphenyl phosphine to significantly improve the aggregation and penetration of Pyrotinib and immunosuppressants in tumors. https://lnkd.in/gFwk8t3v

Adaptimmune has secured FDA approval for Tecelra (afami-cel), a breakthrough in treating metastatic or unresectable synovial sarcoma. Tecelra stands out as the first engineered cell therapy for solid tumors, the first TCR-T therapy on the market, and the first new treatment for this indication in over a decade. This approval is a significant milestone for cell therapy advancements, leveraging Adaptimmune's unique T-cell receptor (TCR) platform to target solid tumor cancers. Synovial sarcoma is a rare form of cancer in which malignant cells develop and form a tumor in soft tissues of the body. The new therapy has shown promising results, with a 43% overall response rate in clinical trials. Read more here: https://lnkd.in/ekxia_YV #Tecelra #Adaptimmune #FDAApproval #CellTherapy #SynovialSarcoma #TCellReceptor

Think you're up-to-date on the latest treatments for ROS1-positive NSCLC? Put your knowledge to the test with our interactive quiz! Challenge yourself and see how well you know the latest advancements and regulatory updates in this critical area of oncology. Questions will cover the only three FDA-approved drugs for treating ROS1 fusion-positive lung cancers. Assess your knowledge of their mechanisms of action, side effect profiles, and pivotal clinical trial results. Ready to prove your expertise? Take the quiz now: https://ow.ly/vbuh50SO8cP #NSCLC #LungCancer #Oncology #TKI #MedicalQuiz #InteractiveLearning

If you're interested in learning more about how our team can help you incorporate ctDNA detection as a surrogate endpoint into your clinical trials, please feel free to reach out! #precisionmedicine #precisiononcology #mrd #ctdna #cancerresearch #genetictesting

Abbisko will be releasing their latest clinical trial data at the ESMO GI Congress in 2024. The data features the use of their independently developed highly selective small molecule FGFR4 inhibitor ABSK011 in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma patients. Known for its high selectivity, ABSK011 is a promising FGFR4 small molecule inhibitor designed for the treatment of advanced solid tumors, particularly those with FGFR4 signaling pathway abnormalities (such as ligand FGF19 amplification/overexpression, FGFR4 mutation/amplification/fusion, etc.) in conditions like late-stage HCC, cholangiocarcinoma, and breast cancer. #QMportfolio #QMhealthcare #ESMOGI2024 #Abbisko #Irpagratinib #CancerResearch #HepatocellularCarcinoma

We are excited to share an interview with the Principal Investigator of the SECuRE trial, Geoff Johnson, MD, PhD, Mayo Clinic, Rochester, MN, recorded by Video Journal of Oncology (VJOncology). In the interview Dr. Johnson provided an overview of the trial at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.   The SECuRE trial is investigating the safety and tolerability of both 64Cu-SAR-bisPSMA to detect and 67Cu-SAR-bisPSMA to treat patients with metastatic castrate-resistant prostate cancer. The trial is currently recruiting into cohort 3, the last cohort to assess a single dose of 67Cu-SAR-bisPSMA at the highest dose level of 12GBq, and will be followed by a multi-dose cohort, pending safety evaluation. ClinicalTrials.gov identifier: NCT04868604. The safety and efficacy of the products investigated in this study have not been assessed by any health authorities. Click here to watch the interview: https://lnkd.in/gSBxgBCX

OS Therapies remains dedicated to developing new treatments for osteosarcoma, bringing hope to those battling this aggressive bone cancer. Our Phase 2b OST-HER2 study in osteosarcoma has received FDA designations: Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD), and Fast Track Designation (FTD). OST-HER2’s strong safety profile supports its potential to become a practical adjuvant therapy to delay or prevent subsequent recurrences and improve overall survival in the very difficult challenge of recurrent osteosarcoma. The trial is fully enrolled with final data expected in Q4-24. https://bit.ly/3A5ScHW  #SarcomaAwareness #Osteosarcoma #CancerResearch #HopeForCures $OSTX